Category
5 articles
Datasheet dilutions are a starting point, not an SOP. In UK laboratories, matrix effects, lot drift and automated platforms make local titration a governance issue as much as a technical one. This opinion piece sets out a pragmatic 2026 framework for treating dilution as evidence to be generated, not instruction to be copied.
Antibody laboratories generate valuable knowledge about validation, lot history and troubleshooting, but much of it disappears when fixed-term researchers move on. A lightweight documentation culture and a shared antibody registry can keep that hard-won experience inside the laboratory.
Affinity constants are useful shorthand, but they do not describe how an antibody will behave in a bivalent assay, in a complex sample matrix or after immobilisation on a plastic surface. UK diagnostic developers need a selection framework that treats avidity, format and interference as first-class variables.
Antibody reagent supply is no longer a procurement afterthought for UK laboratories. This contingency map sets out how research and diagnostic teams can reduce customs friction, cold-chain delays and single-source vendor risk in 2026.
Antibody validation is still too often treated as a final checkbox rather than a design requirement. This opinion piece offers a practical audit for UK laboratories and explains how to build knockout or knockdown evidence into grant applications without inflating the budget.